Acumen Pharmaceuticals (ABOS) Q3 2024 earnings summary

Executive summary

• Sabirnetug, a next-generation monoclonal antibody targeting amyloid-beta oligomers in early Alzheimer's, is in Phase 2 ALTITUDE-AD trial with enrollment expected to complete in H1 2025; subcutaneous Phase 1 study topline results are anticipated in Q1 2025.

• Positive Phase 1 results demonstrated strong target engagement, significant plaque reduction, and biomarker improvements.

• Cash and marketable securities totaled $258.9M–$259M as of September 30, 2024, supporting operations into H1 2027.

• Appointment of Dr. Amy Schacterle as Chief Regulatory Officer and Head of Quality to strengthen regulatory strategy.

• Extended collaborations with Lonza for manufacturing and Halozyme for subcutaneous formulation development.

Financial highlights

• R&D expenses rose to $27.2M for Q3 2024 and $59.2M for the nine months ended September 30, 2024, mainly due to clinical trial and licensing costs.

• G&A expenses were $5M for Q3 2024, up slightly year-over-year.

• Net loss was $29.8M for Q3 2024 and $65.2M for the nine months ended September 30, 2024.

• Net cash used in operating activities was $59M for the nine months ended September 30, 2024.

• Interest income was $11.3M for the nine months ended September 30, 2024.

Outlook and guidance

• Cash reserves are expected to fund operations and clinical development into the first half of 2027.

• ALTITUDE-AD Phase 2 enrollment is targeted for completion in H1 2025; Phase 1 subcutaneous results are expected in Q1 2025.

• No interim analyses or unblinded ARIA data will be reported before study completion to preserve statistical integrity.